152 results
The primary objective of this study is to describe the long-term safety of dupilumab in the treatment of patients with moderate to severe asthma who completed the previous asthma clinical trial, TRAVERSE-LTS12551.
To prospectively study if patients carrying clinically relevant DPYD variants (DPYD*2A, c.2846A>T, c.1236G>A/HapB3, c.1679T>G) are more at risk for developing moderate/severe vesicles or bullae with 5-FU cream.
Local antimycotic treatment of fungal toenail infection is more effective than placebo
Primary Objectives: -To evaluate if the treatment of Low Risk HB can be reduced (Group B1) -To compare different induction treatment regimens for Intermediate risk HB (Group C) -To compare different post induction treatment regimens for…
The aim is to describe the study protocol of a randomized controlled trial testing E-nergEYEze.
In rheumatoid arthritis (RA) patients with insufficient response to disease modifying anti-rheumatic drugs (DMARDs) it is unknown whether addition of tocilizumab (TCZ) to conventional synthetic (cs) DMARDs has superior efficacy compared to addition…
Primary objective:- To assess the efficacy of durvalumab with SoC SBRT compared to placebo with SoC SBRT in terms of PFS in patients with subset of T1 to T3N0 NSCLCOsimertinib cohort:- To assess the efficacy of osimertinib following SoC SBRT by 4…
1) To compare pembrolizumab plus olaparib to abiraterone acetate or enzalutamide with respect to overall survival (OS)2) To compare pembrolizumab plus olaparib to abiraterone acetate or enzalutamide with respect to radiographic progression-free…
The main objective is to determine in what optimal dose PTX should be used in preterm infants suffering from sepsis. Previous clinical studies have already indicated the safety of the drug in preterm infants.
1) To compare pembrolizumab plus enzalutamide versus placebo plus enzalutamide with respect to overall survival (OS)2) To compare pembrolizumab plus enzalutamide versus placebo plus enzalutamide with respect to radiographic progression-free survival…
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on PFS and ORR in subjects with RAI-refractory DTC who have progressed after prior VEGFR-targeted therapy.
Primary Objective:To measure the efficacy provided by nivolumab therapy on its own compared to placebo in participants who have had their stage IIB/C cancer completely removed, and have no evidence of disease, but are at high risk of recurrence.…
To determine the efficacy of ALNTTRSC02 in patients with hATTR amyloidosis by evaluating the effect on neurologic impairment. To determine the efficacy of ALN-TTRSC02 on quality of life, gait speed, neurologic impairment, nutritional status, and…
Key PrimaryPart A• To determine the efficacy of acoramidis (AG10) in the treatment of subjects with symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM) by evaluating the difference between the acoramidis and placebo groups in the change from…
MAIN Trial:Primary:To evaluate whether the efficacy of mirikizumab is superior to placebo in participants with Crohn's disease as assessed by- clinical response by patient reported outcome (PRO) at Week 12 andendoscopic response at Week 52-…
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measured…
Primary Objective: • To compare efficacy of once-weekly KRd (56 mg/m2 ) to twice-weekly KRd (27 mg/m2) in subjects with RRMM with 1 to 3 prior lines of therapyKey Secondary Objectives: • To compare progression-free survival (PFS) between treatment…
To compare the relative efficacy of sonothrombolysis in the acute management of STEMI following primary percutaneous coronary intervention [PCI] in patients with persistent ST elevation compared with standard of care.
Zie protocol, hoofdstuk 3 (Objectives)
The study objectives and endpoints described below will be evaluated for the following treatment regimens:• Arm A: Nivolumab + CCRT followed by nivolumab + ipilimumab maintenance• Arm B: Nivolumab + CCRT followed by nivolumab maintenance• Arm C:…